info@targetmol.com    Tel: (857) 239-0968 / (617) 419-7131
Home > Tyrosine Kinase/Adaptors > c/Kit > Imatinib Mesylate
Imatinib Mesylate  
Catalog No. T1621    CAS 220127-57-1
Pack Size
Availability
Price/USD
Quantity
5mg
In Stock
28.00
100mg
In Stock
60.00
250mg
In Stock
80.00
10mM * 1mL (in DMSO)
In Stock
55.00
25mg
In Stock
49.00
Bulk Size: Please Quote for Discount
Documents and Quality Management
Purity:99.50% COA Datasheet HNMR HPLC MSDS
Biological Activity:

Product Description:

Imatinib mesylate is a tyrosine kinase inhibitor IC50 value of 100 nM, 100 nM, 600 nM for v-Abl, c-kit, PDGFR, respectively [1]. Tyrosine kinase is an enzyme which is a subclass of protein kinase and plays an important role in transferring a phosphate group from ATP to a protein in cells. It is shown that tyrosine kinase plays a pivotal role in the management of disorders in which activation of c-Abl, PDGFR, or c-Kit signaling. Recently, the role of tyrosine kinases in the modulation of growth factor signaling are received more and more attention and gradually become an especial important target.

Target:
v-Abl; PDGFR; c-Kit;
Research Area:
Cancer
Chemical Information:
Molecular Weight 589.71
Formula C29H31N7O·CH4SO3
CAS Number 220127-57-1
Solubility Water: 118 mg/mL (200.09 mM); DMSO: 118 mg/mL (200.09 mM)
Storage 3 years -20°C powder;
2 years -80°C in solvent;
Remark For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ℃ for several month.
Technical Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store Products, and issues that need special attention for cell-based assays and animal experiments.

Product Recommendations
  • GZD824, GZD824 is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I) with IC50...
  • PD-173955, PD173955 is a potent Bcr-Abl inhibitor with IC50 of 1-2 nM, also inhibiting Src activity with IC50 o...
  • DCC-2036 (Rebastinib), DCC-2036 (Rebastinib) is a conformational control Bcr-Abl inhibitor for Abl1(WT) and Abl1(T315I) wit...
  • GZD824 Dimesylate, GZD824 Dimesylate is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I...
  • Radotinib, Radotinib, and sometimes referred to by its investigational name IY5511, is a drug for the treatment...

 

Reference

If you have additional questions, Please send us a message. * Required